Latest News
Interim Report and Half-Year Financial Results
Feb 25th, 2021
Starpharma today released its interim report and financial results for the half-year ended 31 December 2020.
Read MoreVIRALEZE™ antiviral nasal spray registered in Europe
Feb 23rd, 2021
Starpharma announced today it had received confirmation that the VIRALEZE™ antiviral nasal spray has been successfully registered for sale in Europe, including in the UK.
Read MoreStarpharma signs DEP® ADC Research Agreement with MSD
Feb 12th, 2021
Starpharma today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.
Read More
AZD0466 clinical DEP® program global expansion
Feb 9th, 2021
Starpharma today announced that it had been advised by AstraZeneca of its intention to expand the clinical program for AZD0466 to include a multi-centre global Phase 1 study. The study will recruit patients with acute leukaemias.
Read More